The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 04, 2025
Filed:
Dec. 11, 2020
Fondazione Istituto Italiano Di Tecnologia, Genoa, IT;
Tes Pharma S.r.l., Perugia, IT;
Alma Mater Studiorum—universita' Di Bologna, Bologna, IT;
Istituto Europeo Di Oncologia S.r.l., Milan, IT;
Andrea Cavalli, Genoa, IT;
Domenico Milano, Genoa, IT;
Marcella Manerba, Genoa, IT;
Greta Bagnolini, Genoa, IT;
Jose Antonio Ortega Martinez, Genoa, IT;
Marinella Roberti, Bologna, IT;
Giuseppina Di Stefano, Bologna, IT;
Roberto Pellicciari, Perugia, IT;
Francesca De Franco, Perugia, IT;
Saverio Minucci, Perugia, IT;
Pier Giuseppe Pelicci, Milan, IT;
Viola Previtali, Genoa, IT;
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, Genoa, IT;
TES PHARMA S.R.L., Perugia, IT;
ALMA MATER STUDIORUM—UNIVERSITA' DI BOLOGNA, Bologna, IT;
ISTITUTO EUROPEO DI ONCOLOGIA S.R.L., Milan, IT;
Abstract
The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular for the use in the treatment of diseases or disorders wherein disrupting Rad51-BRCA2 interaction is beneficial.